Drug Profile
Research programme: CNS disorder therapeutics - Allgenesis Biotherapeutics
Alternative Names: AG 12896Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Allgenesis Biotherapeutics
- Class Antidementias; Neuroprotectants; Small molecules
- Mechanism of Action Amyloid beta-protein precursor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Alzheimer's-disease in Taiwan
- 01 Aug 2017 Preclinical trials in Alzheimer's disease in Taiwan before August 2017 (Allgenesis Biotherapeutics pipeline, August 2017)
- 17 Mar 2017 Early research in CNS disorders in Taiwan (unspecified route)